EAM
MCRB icon

Erste Asset Management’s Seres Therapeutics MCRB Stock Holding History

Erste Asset Management’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,350
Closed -$235K – 565
2021
Q4 		$235K Hold
1,350
– – ﹤0.01% 485
2021
Q3 		$184K Hold
1,350
– – ﹤0.01% 478
2021
Q2 		$645K Hold
1,350
– – 0.01% 383
2021
Q1 		$525K Hold
1,350
– – 0.01% 383
2020
Q4 		$661K Buy
+1,350
New +$791K 0.02% 366

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Erste Asset Management's MCRB Position: Q1 2022 in Review

Erste Asset Management sold out of Seres Therapeutics (MCRB) in Q1 2022, closing a stake of 1,350 shares — an estimated $235K sold.

Erste Asset Management first reported a position in MCRB in Q4 2020 and held it in 5 quarters. The position peaked at $661K in Q4 2020. 131 funds tracked by Wall St. Rank hold MCRB as of Q1 2022.

  • Erste Asset Management reported no remaining Seres Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Erste Asset Management sold 1,350 Seres Therapeutics shares in Q1 2022, an estimated $235K.
  • Erste Asset Management first reported a position in Seres Therapeutics in Q4 2020 and held it in 5 quarters.
  • Erste Asset Management's Seres Therapeutics position peaked at $661K in Q4 2020.
  • 131 funds tracked by Wall St. Rank held Seres Therapeutics as of Q1 2022.

Based on Erste Asset Management's 13F filing for Q1 2022, filed 25 Nov 2024.